Analyst Ratings For Miragen Therapeutics Inc (NASDAQ:MGEN)
Today, B. Riley initiated coverage on Miragen Therapeutics Inc (NASDAQ:MGEN) with a Buy with a price target of $18.50.
There are 7 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Miragen Therapeutics Inc (NASDAQ:MGEN) is Buy with a consensus target price of $16.4167 per share, a potential 421.16% upside.
Some recent analyst ratings include
- 12/31/2018-Miragen Therapeutics Inc (NASDAQ:MGEN) has coverage initiated with a Buy ➝ Buy rating and $18.50 price target
- 10/8/2018-Miragen Therapeutics Inc (NASDAQ:MGEN) had its Outperform rating reiterated by Wedbush with a $19.00 price target
- 4/9/2018-Miragen Therapeutics Inc (NASDAQ:MGEN) had its Hold rating reiterated by Cowen
- 3/29/2018-Miragen Therapeutics Inc (NASDAQ:MGEN) has coverage initiated with a Buy ➝ Buy rating and $14.00 price target
- 3/22/2018-Miragen Therapeutics Inc (NASDAQ:MGEN) has coverage initiated with a Buy rating and $15.00 price target
- 3/9/2018-Miragen Therapeutics Inc (NASDAQ:MGEN) has coverage initiated with a Outperform ➝ Outperform rating and $19.00 price target
- 1/16/2018-Miragen Therapeutics Inc (NASDAQ:MGEN) had its Buy rating reiterated by Chardan Capital
- On 10/11/2018 Thomas E Hughes, Director, bought 10,000 with an average share price of $4.77 per share and the total transaction amounting to $47,700.00.
- On 2/13/2018 Adam Scott Levy, Insider, bought 9,090 with an average share price of $5.50 per share and the total transaction amounting to $49,995.00.
- On 2/13/2018 Bruce Booth, Director, bought 545,454 with an average share price of $5.50 per share and the total transaction amounting to $2,999,997.00.
- On 12/20/2017 Thomas E. Hughes, Director, sold 12,000 with an average share price of $8.00 per share and the total transaction amounting to $96,000.00.
- On 6/22/2017 Adam Scott Levy, Insider, bought 200 with an average share price of $7.55 per share and the total transaction amounting to $1,510.00.
- On 3/10/2017 Kyle Lefkoff, Director, sold 5,800 with an average share price of $14.34 per share and the total transaction amounting to $83,172.00.
- On 3/8/2017 Kyle Lefkoff, Director, sold 15,000 with an average share price of $15.40 per share and the total transaction amounting to $231,000.00.
About Miragen Therapeutics Inc (NASDAQ:MGEN)
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.
Recent Trading Activity for Miragen Therapeutics Inc (NASDAQ:MGEN)
Shares of Miragen Therapeutics Inc closed the previous trading session at 3.05 up +0.37 13.81% with 181098 shares trading hands.
